Tao Dao, Guangyan Xiong, Sung Soo Mun, Jeremy Meyerberg, Tatyana Korontsvit, Jingyi Xiang, Ziyou Cui, Aaron Y Chang, Casey A Jarvis, Winson Cai, Hanzhi Luo, Aspen J Pierson, Anthony F Daniyan, Sarah Yoo, Sumiko Takao, Michael Gregory Kharas, Alex Kentsis, Cheng Liu, David A Scheinberg
Chimeric antigen receptor T cell (CAR T) therapy has produced remarkable clinical responses in B cell neoplasms. However, many challenges limit this class of agents for the treatment of other cancer types, in particular the lack of tumor-selective antigens for solid tumors and other hematological malignancies, such as Acute Myeloid Leukemia (AML), that may be addressed without significant risk of severe toxicities while providing sufficient abundance for efficient tumor suppression. One approach to overcome this hurdle is dual targeting by an antibody-T cell receptor (AbTCR) and a chimeric costimulatory signaling receptor (CSR) to two different antigens, in which both antigens are found together on the cancer cells, but not together on normal cells...
December 4, 2023: Blood